Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a postoperative recurrence thereof.此處敘述抗癌胜肽疫苗。特別是,提供來自MYBL2基因之抗原決定位胜肽,其與HLA抗原結合且具有細胞毒殺性T淋巴球誘發能力,更特別是胜肽具有序列辨識號:5之胺基酸序列與其片段。本發明更擴展至提供包括一、二或數個胺基酸插入、取代或添加至上述胜肽或片段的胜肽,它們維持細胞毒殺性T淋巴球誘發能力。也提供編碼出任何上述胜肽的核酸、抗原呈現細胞與以此類胜肽為目標之經分離的細胞毒殺性T淋巴球,及包括任何上述胜肽、核酸與抗原呈現細胞為活性成分。本發明之成分具有與癌症(腫瘤)之治療及/或預防(即,避免),及/或其手術後復發的避免相關之特別效用。
